Non-Small Cell Lung Cancer
Researchers from Vanderbilt University describe findings in non-small cell lung cancer
Published in Clinical Trials Week, May 11th, 2009
"In a single-institution phase II study, we sought to determine the effectiveness of concurrent chemoradiation given with celecoxib and examined biomarkers to predict response to COX-2 inhibition. Seventeen patients with stage IIIA or IIIB non-small cell lung cancer (NSCLC) were enrolled in the study. All received 400 mg celecoxib twice daily continuously while on trial in addition to concurrent chemoradiation...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2009-05-11)
More Articles from Clinical Trials Week
- Ardea Biosciences, Inc.
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors - Breast Cancer
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial - Genta Incorporated
Genta Announces Presentations for Two Lead Compounds, Genasense® and Tesetaxel, at 2009 Annual ASCO Meeting - Isis Pharmaceuticals, Inc.
Isis and Collaborators Present New Research at the ATVB Annual Conference - Synexus
Synexus Ability to Handle the Whole of a Phase II Trial Slashes Time and Costs - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
